Caladan Therapeutics

Caladan Therapeutics is an early-stage bioprocessing technology company founded in 2021 and based in Cambridge, MA. The company's core offering is the Caladan 250, a modular, automated benchtop bioreactor system designed to streamline bioprocess development for synthetic biology and therapeutic applications. By integrating hardware, intuitive no-code software, and automation, Caladan aims to reduce complexity, lower costs, and increase experimental throughput for its customers. The company appears to be pre-revenue, focusing on customer acquisition and platform deployment within the rapidly growing industrial biology and biopharma R&D sectors.

Integrated bioprocessing platform featuring modular 250mL benchtop bioreactors, no-code experiment design software, and advanced automation for real-time monitoring and sampling.

Caladan competes in the benchtop bioreactor and bioprocess automation market, which is dominated by large players like Sartorius (BIOSTAT STR), Thermo Fisher Scientific (HyPerforma), and Eppendorf (BioFlo). Its differentiation lies in its modularity for parallel processing, integrated no-code software, and a value proposition focused on doubling throughput on the same budget.